NCT03381547

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.

Detailed description

An open label, randomized, single dose, 3-way crossover study to evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.

Conditions

• Healthy Adult Subjects

Interventions

Type	Name	Description
BIOLOGICAL	Pegilodecakin	Pegilodecakin Alone

Timeline

• Start date: 2017-12-18
• Primary completion: 2018-02-11
• Completion: 2018-02-11
• First posted: 2017-12-22
• Last updated: 2019-04-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study